|Home | About | Journals | Submit | Contact Us | Français|
The Ig-ITIM family member PECAM-1 is expressed in vascular and endothelial cells, and its functions include suppression of mitochondria-dependent apoptosis. Previous studies have identified distinct PECAM-1 cytoplasmic domain splice variants at the mRNA, but not protein, level. Several relatively abundant mRNA isoforms lack exon 15 (Δ15) and would theoretically encode a protein with a truncated cytoplasmic domain and a unique C-terminal sequence. Using a novel rabbit polyclonal antibody that specifically recognizes Δ15 PECAM-1, we found that the Δ15 PECAM-1 isoform was expressed in human tissues, including brain, testes and ovary. This isoform was also expressed on the cell surface of human platelets, human umbilical vein endothelial cells (HUVECs) and the Jurkat T-cell leukemia, human erythroleukemia (HEL) and U937 histiocytic lymphoma cell lines. Furthermore, murine platelets and lung lysates demonstrated abundant amounts of exon-15-deficient PECAM-1. Functional studies revealed that Δ15 PECAM-1 retains both its homophilic binding capacity and its ability to signal by means of its immunoreceptor tyrosine-based inhibitory motif (ITIM) domains. Δ15 PECAM-1 was unable, however, to protect against apoptosis induced by overexpression of Bax or treatment with the chemotherapy agent etoposide. These studies suggest a novel role for the PECAM-1 C-terminus in cytoprotective signaling and highlight a need for further characterization of expression of PECAM-1 isoforms in normal and malignant tissues.
Platelet/endothelial cell adhesion molecule (hereafter referred to as PECAM-1; also known as PECA1 or CD31) is a 130-kDa cell-surface protein that is a member of the immunoglobulin immunoreceptor tyrosine-based inhibitory motif (Ig-ITIM)-containing family (Newman, 1999). PECAM-1 is expressed on endothelial cells and a variety of hematopoietic cells, including most human CD34+ hematopoietic progenitor cells (Watt et al., 1993). PECAM-1 expression is maintained at relatively high levels on cells of the myeloid and megakaryocytic lineages but is selectively lost during erythroid and B-cell (Jackson et al., 2000) differentiation. Mature human platelets constitutively express 5000 to 10,000 PECAM-1 molecules per cell (Mazurov et al., 1991; Metzelaar et al., 1991; Newman, 1994), whereas monocytes and neutrophils display 50,000 to 100,000 molecules per cell under resting conditions. PECAM-1 is also expressed in certain T-cell subsets (Tanaka et al., 1992; Torimoto et al., 1992; Zehnder et al., 1992) and is a major constituent of the intercellular junction of endothelial cells (Muller et al., 1989; Albelda et al., 1990; Newman et al., 1990; Newman, 1994). Interestingly, PECAM-1 has also been shown to be expressed in human cytotrophoblasts (Zhou et al., 1997a; Zhou et al., 1997b), spermatozoa (Nixon et al., 2005) and brown adipose tissue (Rosso and Lucioni, 2006).
PECAM-1 functions to negatively regulate immunoreceptor tyrosine-based activating motif (ITAM) signaling pathways in platelets (Patil et al., 2001; Jones et al., 2001) and lymphocytes (Newton-Nash and Newman, 1999; Henshall et al., 2001; Wilkinson et al., 2002). PECAM-1 also contributes to leukocyte transendothelial migration (Muller and Randolph, 1999; O'Brien et al., 2003), modulates integrin-mediated cell adhesion (Tanaka et al., 1992; Leavesley et al., 1994; Berman and Muller, 1995; Berman et al., 1996; Varon et al., 1998; Chiba et al., 1999; Zhao and Newman, 2001; Dangerfield et al., 2002) and plays a role in angiogenesis (DeLisser et al., 1997; Zhou et al., 1999; Cao et al., 2002). At the physiological level, PECAM-1 protects against septic shock (Maas et al., 2005; Carrithers et al., 2005) and modulates reactive oxygen species produced by coronary microvessels (Liu et al., 2006). Recent studies also indicate that PECAM-1 can protect against cell death in a variety of systems, and its presence can influence a number of classical cell-survival pathways (Noble et al., 1999; Bird et al., 1999; Evans et al., 2001; Ferrero et al., 2003; Gao et al., 2003; Limaye et al., 2005; Bergom et al., 2006).
The extracellular domain of full-length (WT) PECAM-1 consists of six immunoglobulin (Ig)-like domains. Ig domain 1 mediates PECAM-1 trans-homophilic binding (Sun, J. et al., 1996; Sun, Q. et al., 1996; Newton et al., 1997), and antibodies against this region diminish transendothelial migration of leukocytes (Muller et al., 1993; Vaporciyan et al., 1993; Bogen et al., 1994; Liao et al., 1995) and angiogenesis in vivo (Zhou et al., 1999). The PECAM-1 cytoplasmic domain is complex (Kirschbaum et al., 1994), in that it is encoded by eight short exons that exhibit differing susceptibilities to alternative splicing (Baldwin et al., 1994). In its full-length, unspliced form, the cytoplasmic domain contains 118 amino acids, including two ITIM domains and several other sites for posttranslational modifications. A plethora of signaling cascades have been found to emanate from events initiated by cytosolic signaling molecules that associate with the cytoplasmic tail of PECAM-1 (Gibbins, 2002; Jackson, 2003; Newman and Newman, 2003).
Previous studies in a number of laboratories have shown the existence of alternatively spliced PECAM1 mRNAs in human and murine hematopoietic cells, murine embryos and tissues, and human tissues and endothelial cells (reviewed in Newman and Newman, 2003). Such mRNA species are relatively abundant at certain developmental stages (Baldwin et al., 1994) and in certain tissues (Sheibani et al., 1997; Sheibani et al., 1999; Robson et al., 2001; Wang and Sheibani, 2002; Li et al., 2005) and have the potential to encode PECAM-1 isoforms that differ markedly in their biological properties; however, the lack of isoform-specific reagents has limited the detection of PECAM-1 isoforms at the protein level. Notably, all of the exons encoding the cytoplasmic domain of PECAM-1 are phase 1 exons – that is, they end with a nucleotide that becomes part of the first triplet in the codon encoded by the following exon (Fig. 1) – with the exception of exon 15, which is a phase 0 exon. Splicing out of exon 15, therefore, results not only in loss of the amino acids normally encoded by exon 15 but also in a change in the reading frame of downstream exon 16 such that it now encodes a novel C-terminal sequence that ends in the amino acids ENGRLP. Because of the potential for variant PECAM-1 isoforms to confer distinct adhesive and signaling properties to the vascular cells in which they are expressed, we sought to determine whether a PECAM-1 isoform that is missing exon 15 (Δ15) is expressed as a protein in human and murine tissues and, if so, whether it functions differently in its ability to protect cells from apoptosis – a property previously shown to require the PECAM-1 cytoplasmic domain (Bergom et al., 2006). We report herein a potential role for the C-terminal region of PECAM-1 in cytoprotective signaling that might have implications for the expression of different PECAM-1 isoforms during embryogenesis, development and the progression of cancer.
PECAM1 mRNA splice variants have been reported in a variety of studies (Li et al., 2005; Yan et al., 1995a; Sheibani et al., 1999; Robson et al., 2001; Newman et al., 1987; Goldberger et al., 1994; Baldwin et al., 1994; Wang and Sheibani, 2002; Wang et al., 2003; Wang et al., 2004; Kirschbaum et al., 1994; Aroca et al., 1999), sometimes being present at relatively high levels (Li et al., 2005; Sheibani et al., 1999; Robson et al., 2001; Wang and Sheibani, 2002). We sought to determine whether isoforms lacking exon 15 were also expressed at the protein level in human and murine tissues. Exon 15 is out of phase with its upstream and downstream exons; thus, its deletion generates a novel C-terminal peptide, ENGRLP (Fig. 1A,B). Using this novel C-terminal peptide as an immunogen, we were able to generate a rabbit polyclonal antibody that is highly specific for PECAM-1 isoforms that lack exon 15. As shown in Fig. 1C, this polyclonal antibody against Δ15 PECAM-1 specifically detects the product of an enforced cDNA that encodes Δ15 PECAM-1 but not full-length PECAM-1.
Using this Δ15 PECAM-1-specific antibody, we were able to examine the expression of Δ15 PECAM-1 in human tissues. Lysates prepared from normal human tissues were analyzed by western blot for expression of full-length and Δ15 PECAM-1 isoforms. In addition, using cell-surface immunoprecipitation, we examined the expression of Δ15 PECAM on human platelets, human umbilical vein endothelial cells (HUVECs) and the Jurkat T-cell leukemia, human erythroleukemia (HEL) and U937 histiocytic lymphoma cell lines. As shown in Fig. 2A, lysates of human ovaries exhibit moderate levels of PECAM-1, with only a small percentage being the Δ15 PECAM-1 isoform. By contrast, human brain and cultured HUVECs contain a much greater proportion of Δ15 PECAM-1. Spleen and lung lysates have little or no Δ15 PECAM-1, whereas human testes express a small amount of both Δ15 and WT PECAM-1 isoforms. The hematopoietic cancer cell lines express variable proportions of Δ15 PECAM-1, with Jurkat cells having only a fraction of this isoform, and HEL and U937 cells having a large proportion of Δ15 PECAM-1. Interestingly, whereas human platelets express predominantly WT PECAM-1 (Fig. 2A), murine platelets express abundant amounts of the Δ15 isoform (Fig. 2B). From these data, we conclude that the Δ15 isoform of PECAM-1 is present at the cell surface and is expressed at substantial levels in select human and murine tissues. This led us to examine the physiological consequences, if any, of expressing Δ15 PECAM-1.
The PECAM-1 cytoplasmic domain transduces intracellular signals by becoming tyrosine phosphorylated on its paired ITIM domains and recruiting signaling molecules containing Src-homology 2 (SH2) domains, most notably the protein-tyrosine phosphatase SHP-2 (Jackson et al., 1997b; Masuda et al., 1997; Sagawa et al., 1997). Although the Δ15 form of PECAM-1 lacks both exons 15 and 16, it has intact ITIM domains, which are located within exons 13 and 14 (Fig. 1B). As shown in Fig. 3, the Δ15 PECAM-1 isoform becomes tyrosine phosphorylated in response to pervanadate stimulation at least as well as does WT PECAM-1. The absence of tyrosine phosphorylation on the ITIM-less (Y663,668F) form of PECAM-1 indicates that these ITIM tyrosine residues are the only phosphorylated sites on full-length PECAM-1, confirming earlier studies (Jackson et al., 1997a). Fig. 3 also demonstrates that SHP-2 is able to be recruited by both WT and Δ15 forms of PECAM-1 when they are tyrosine phosphorylated. As binding of SHP-2 to PECAM-1 requires that both ITIM tyrosine residues be phosphorylated (Jackson et al., 1997a), these data predict that Δ15 PECAM-1 should be able to transmit ITIM-dependent signals.
We have previously reported that the PECAM-1 extracellular domain is all that is required to localize PECAM-1 to cell-cell borders, as neither deletion nor substitution mutations within the cytoplasmic domain had effects on the localization of PECAM-1 to cell-cell junctions (Sun et al., 2000). By contrast, a single lysine-to-alanine mutation within the homophilic-binding Ig domain 1 (K89A) prevents PECAM-1 from accumulating at cell-cell junctions (Sun et al., 2000). Using REN mesothelioma cell lines (Gurubhagavatula et al., 1998; O'Brien et al., 2001) stably transfected with human WT, ITIM-less, Δ15 and K89A forms of PECAM-1, we examined the subcellular localization of PECAM-1 using confocal immunofluorescence microscopy. As shown in Fig. 4, there is no detectable difference in the ability of WT, ITIM-less or Δ15 PECAM-1 to concentrate at cell-cell borders. As expected, because K89A PECAM-1 lacks homophilic binding capability, it is distributed over the entire plasma membrane (Fig. 4D). Thus, Δ15 PECAM-1 retains normal homophilic binding characteristics and junctional localization, becomes tyrosine phosphorylated and recruits SHP-2 upon activation.
PECAM-1 has previously been shown to confer cytoprotection to cells subjected to the mitochondria-dependent, intrinsic pathway of apoptosis (Gao et al., 2003). However, recent work has shown that, at least in certain systems, the PECAM-1–SHP-2 signaling complex might not fully account for the cytoprotective effects of PECAM-1 (Bergom et al., 2006). To determine whether the changes in the Δ15 cytoplasmic domain alter intracellular survival signals emanating from PECAM-1, we examined whether Δ15 PECAM-1 is able to protect cells efficiently against cell death induced by overexpression of Bax in a HEK293T cell model system (Gao et al., 2003). As shown in Fig. 5A, whereas WT PECAM-1 is able to reduce apoptosis induced by Bax overexpression by ~40%, Δ15 PECAM-1 failed to protect against Bax-induced cell death. The ITIM-less form of PECAM-1 also failed to protect against cell death, as reported previously (Gao et al., 2003). These data demonstrate that both ITIM-mediated signals as well as the WT C-terminus of PECAM-1 are important for PECAM-1-mediated protection against apoptosis induced by overexpression of Bax in these cells.
Because we have recently found that PECAM-1 expression confers resistance to chemotherapy-induced apoptosis (Bergom et al., 2006), we next examined whether Δ15 PECAM-1 is able to confer resistance to chemotherapy-induced cell death to the same extent as WT PECAM-1. REN cells expressing similar amounts of WT and Δ15 PECAM-1 (Fig. 5B) were stimulated with the genotoxic chemotherapeutic drug etoposide and apoptosis was then assessed. As shown in Fig. 5C, Δ15 PECAM-1 conferred significantly less cytoprotection than did its WT counterpart. Taken together, these data demonstrate that Δ15 PECAM-1 lacks the full anti-apoptotic function conferred by WT PECAM-1, suggesting a novel role for the wild-type C-terminal region of PECAM-1 in cytoprotective signaling.
Here, we sought to determine whether the Δ15 PECAM-1 isoform is expressed at the protein level in human and murine tissues and whether human Δ15 PECAM-1 produces different signals compared with WT PECAM-1. Because the Δ15 form of PECAM-1 ends in a unique C-terminus, we were able to develop a novel antibody specific for forms of PECAM-1 that lack exon 15 (Fig. 1).
Using the Δ15 PECAM-1-specific antibody, we demonstrate here that a variety of human and murine tissues do indeed express Δ15 PECAM-1 protein (Fig. 2). Initially, tissue lysates were examined for reactivity with the Δ15 PECAM-1 antibody. The results from these studies merely indicated that this protein was synthesized by cells, but they did not demonstrate that the protein traffics to the cell surface. Therefore, we also immunoprecipitated PECAM-1 from whole cells and subsequently immunoblotted for Δ15 PECAM-1 to determine whether Δ15 PECAM-1 is present at the surface of primary cells and cell lines. Notably, human brain tissue expresses a substantial amount of Δ15 PECAM-1. The cells on which Δ15 PECAM-1 is expressed in the brain could include not only endothelium but also microglial or other central nervous system cells. Human ovary and testes also express Δ15 PECAM-1. When compared with the total amount of PECAM-1 present in human testes tissue, the amount of the Δ15 isoform expressed appears to be proportionally large. The role that PECAM-1 plays in human reproductive tissues is largely unknown, but prior work has demonstrated that PECAM-1 is expressed in human spermatozoa and that PECAM-1 might in part be responsible for capacitation-associated signaling cascades (Nixon et al., 2005). In addition, PECAM-1 expression has been described in subpopulations of cytotrophoblasts (Zhou et al., 1997a; Zhou et al., 1997b). HUVECs also have a relatively small, but easily detectable, amount of Δ15 PECAM-1 protein, and human cancer cell lines can express substantial amounts of Δ15 PECAM-1 on the cell surface. Taken together, these data suggest that the proportion of Δ15 PECAM-1 expressed varies in different vascular beds.
Most strikingly, murine, but not human, platelets and lung tissue from C57BL/6 mice express a considerable proportion of PECAM-1 that lacks exon 15 (Fig. 2B). This might have wide-ranging implications for the way in which prior studies of PECAM-1 function in murine tissues have been interpreted, most of which have been performed in the C57BL/6 strain. Interpretation of these studies was based on the assumption that the majority of PECAM-1 in WT mice is the full-length form. It is not known whether other murine strains also express such large proportions of exon-15-deficient PECAM-1 protein, although, in platelets from FVB/N and C129 strains, the majority of PECAM1 mRNA lacks exon 15 (Wang and Sheibani, 2002). Interestingly, studies examining the effect of PECAM-1 on leukocyte transmigration found that C57BL/6, but not FVB/N, mice are uniquely able to compensate for the loss of PECAM-1 function (Schenkel et al., 2004). It is possible that WT mouse strains express a different array of isoforms of PECAM-1 in leukocytes and/or in endothelial cells, and this in part accounts for the differences in leukocyte transmigration seen between strains. PECAM-1 has also been implicated in modulating platelet signaling (Falati et al., 2006; Jones et al., 2001; Patil et al., 2001), as well as murine megakaryocytopoiesis (Dhanjal et al., 2007; Wu et al., 2007). Once again, it is not known whether certain alternatively spliced isoforms of PECAM-1 are more efficient than others at eliciting these responses. Because the data in Fig. 2 demonstrate that isoforms lacking exon 15 are differentially expressed at the protein level in a variety of human and murine tissues, re-examination of the ability of Δ15 PECAM-1 to signal might be warranted.
Many of the functions of PECAM-1 stem from its ability to bind homophilically to other PECAM-1 molecules and to signal by means of its cytoplasmic ITIMs. Thus, we sought to determine whether the Δ15 isoform of PECAM-1 can similarly perform these functions. Prior studies of murine Δ15 PECAM-1 in Madin-Darby canine kidney (MDCK) cells indicated that it is unable to localize to adherens junctions when compared with murine Δ14,15 PECAM-1 (Sheibani et al., 2000). Unfortunately, these studies did not compare Δ15 PECAM-1 with WT PECAM-1, and the human counterparts of these isoforms were not examined in human cells. In the present investigation, human Δ15 PECAM-1 became concentrated normally at cell-cell borders in human cells, and cells expressing Δ15 PECAM-1 largely exhibited a similar morphology to those cells expressing WT PECAM-1 (Fig. 4). In addition, we determined that human Δ15 PECAM-1 can signal through its ITIM domains (Fig. 3). This suggests that the functions of human PECAM-1 that are mediated merely by extracellular region engagement and/or ITIM-mediated signaling might be largely intact in cells expressing the Δ15 PECAM-1 isoform.
Both ITIM-mediated signals and homophilic binding have previously been shown to be required for PECAM-1 to protect efficiently against programmed cell death (Gao et al., 2003). However, even though Δ15 PECAM-1 retains the ability to both signal through its ITIM domains (Fig. 3) and localize to cell-cell borders (Fig. 4), it surprisingly lacks the full cytoprotective function when compared with WT PECAM-1, when apoptosis is induced both by overexpression of Bax and by treatment with a chemotherapy agent (Fig. 5). This suggests a novel role for the C-terminal region of the PECAM-1 cytoplasmic domain in PECAM-1-mediated cytoprotection. While it is unclear what this role might be, it is tempting to speculate that failure to recruit a cytosolic binding partner that normally associates with an amino acid sequence found in WT, but not Δ15, PECAM-1 accounts for this difference. Identification of such proteins is the subject of current investigations.
A diminished ability to exhibit cytoprotection is one of several potential functional variations between WT and Δ15 PECAM-1. Further studies will be necessary to determine whether expression of Δ15 PECAM-1 has additional functional consequences. Even if further differences are uncovered between these PECAM-1 isoforms, the phenotypic effect might be minimal unless the Δ15 PECAM-1 is expressed at high levels or exhibits dominant-negative or positive effects. However, our results demonstrate that large relative fractions of exon-15-deficient PECAM-1 are expressed in at least a few cell types. It is in these tissues where functional differences are more likely to result in a change of cellular phenotype.
Taken together, the data in the present investigation demonstrate, first, that Δ15 PECAM-1 is expressed in both murine and human tissues and cell lines and, second, that Δ15 PECAM-1 retains homophilic binding characteristics and is able to signal through its ITIM domains, yet, despite this, it fails to offer appreciable cytoprotection against apoptosis when compared with WT PECAM-1. These studies suggest a novel role for the C-terminal region of the PECAM-1 cytoplasmic domain in cytoprotective signaling and highlight a need for further studies on the implications of the expression of this, sometimes abundant, alternatively spliced isoform of PECAM-1. The Δ15-specific antibody against PECAM-1 described here is one tool that can aid in the characterization of the expression of PECAM-1 isoforms in cancers and other tissues.
Human tissue lysates were purchased from Research Diagnostics (Flanders, NJ) and prepared following the manufacturer's instructions. Complete Protease Inhibitor Cocktail tablets were from Roche Applied Science (Indianapolis, IN). Cell culture reagents were purchased from Mediatech (Herndon, VA), and all other reagents were from Sigma-Aldrich (St Louis, MO) unless otherwise specified.
Anti-PECAM-1 monoclonal antibody (mAb) 390 (Baldwin et al., 1994) was a kind gift from Steven M. Albelda (University of Pennsylvania School of Medicine). Rabbit anti-human SHP-2 (C-18) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish-peroxidase-conjugated anti-phosphotyrosine antibody (PY-20) was purchased from Zymed Laboratories (South San Francisco, CA). Rabbit anti-human Bax and β-tubulin antibodies were from Pharmingen/BD Biosciences (Bedford, MA). PECAM-1-specific mAb 1.3 and rabbit polyclonal anti-human PECAM-1 have been extensively characterized and described previously (Jackson et al., 1997a; Yan et al., 1995b).
A murine mAb specific for murine PECAM-1 (muPECAM-1) was prepared by immunizing PECAM-1-deficient mice (Duncan et al., 1999) with purified muPECAM-1. muPECAM-1 was purified on a mAb 390 affinity column from a lysate of muPECAM-1-transfected L-cells (Baldwin et al., 1994). The column was prepared using an ImmunoPure Protein G IgG Plus Orientation Kit from Pierce Biotechnology (Rockford, IL). The immunogen comprised purified muPECAM-1 reduced with 10 mM dithiothreitol (DTT) and alkylated with 30 mM iodoacetamide, mixed with an equal amount of nonreduced muPECAM-1.
A human Δ15 PECAM-1 construct was produced using standard gene splicing by extension overlap PCR techniques. Using PECAM-1 in pcDNA3 as a template, Δ15 PECAM-1 was created using the PECAM-1 primer #1 (5′-GAGAAAAAGAGGCAAACCC-3′) and exon 14-16 reverse primer (5′-AAGGGAGCCTTCCGTTCTCAGGGACAGCTTTCCGGA-3′). A second product was prepared using exons 14-16 (5′ -TCCGGAAAGCTGTCCCTGAGAACGGAAGGCTCCCTT-3′) and PECAM-1 primer #2 (5′-CCCTCTGTATCTCTTTCTAC-3′). The products of both of these reactions were mixed together with PECAM-1 primer #3 (5′-ATGCCAGTGGAAATGTCC-3′) and PECAM-1 primer #2, and a secondary overlap PCR was performed. The final amplified product was digested with Tth111I and Bsu36I (New England Biolabs, Ipswich, MA) into a similarly digested WT PECAM-1 cDNA cloned into pGEM7. This mutated PECAM-1 cDNA was removed from pGEM7 with EcoRI and inserted into the mammalian expression vector pcDNA3 (Invitrogen, Carlsbad, CA) within the multiple cloning site at EcoRI. The constructs were confirmed by nucleotide sequencing.
In order to create a rabbit polyclonal antibody specific for the unique C-terminus of Δ15 PECAM-1, a peptide was synthesized using standard FMOC protocols on an ABI 433 instrument. Peptide mass was verified by MALDI-TOF mass spectrometry. The peptide sequence, C-GGG-ENGRLP, contained a C for coupling to the hapten carrier maleimide-activated KLH, along with a GGG spacer for increased immunogenicity. The polyclonal antibody serum was prepared by Cocalico Biologicals (Reamstown, PA).
The human HEK293, HEL, U937 and Jurkat cells were obtained from the American Type Culture Collection (Manassas, VA), and the human REN mesothelioma cells (Smythe et al., 1994) were a kind gift from Steven Albelda (Department of Medicine, University of Pennsylvania). Cells were cultured in DMEM (HEK293) or RPMI media containing 10% heat-inactivated fetal bovine serum and 40 mg/ml gentamicin. Human umbilical vein endothelial cells (HUVECs) were cultured as described previously (Maas et al., 2003).
Stable REN cell lines were established by transfecting cells as described previously (Bergom et al., 2006). The PECAM-1-expressing cells were then sorted using fluorescence activated cell sorting (FACS) (FACSDiVa, BD Biosciences) to obtain a mixed population of cells that express PECAM-1.
Lysates were prepared from HEK293 cells stably transfected with either human PECAM-1 or Δ15 PECAM-1 (Maas et al., 2003). PECAM-1 was immunoprecipitated with PECAM-1.3 (Jackson et al., 1997a) incubated overnight at 4°C. Platelets were isolated as described previously (Rathore et al., 2003). Whole-cell immunoprecipitation was performed on human platelets, HUVECs, Jurkat, HEL and U937 cells. PECAM-1 1.3 mAb was added to cell suspensions at 10 μg/ml and incubated for 90 minutes. The cells were then washed and lysed with Triton X-100 lysis buffer. Murine lungs were harvested from C57BL/6 mice that had been perfused with saline. The lungs were placed in hypotonic lysis buffer (25 mM HEPES, 10 mM EDTA pH 7.5) with protease inhibitors and sonicated. An equal volume of 2× Triton X-100 lysis buffer was added. The sample was mixed for 90 minutes at 4°C and insoluble proteins removed by centrifugation. muPECAM-1 was immunoprecipitated with mAb 390.
Normal human tissue lysates (Research Diagnostics) were prepared according to the manufacturer's instructions, and 50 μg of lysate was loaded per lane. All immunoblotting results are representative of at least two independent experiments.
REN cell lines stably expressing human WT, ITIM-less, K89A or Δ15 PECAM-1 were cultured in Falcon culture slides (BD Biosciences) and allowed to grow to confluence. Cells were prepared as described previously (Maas et al., 2003). Slides were examined with a Leica TCS SP2 confocal microscope with a 100× oil-immersion lens and analyzed with MetaMorph software (Molecular Devices, Sunnyvale, CA).
REN cells stably transfected with PECAM-1 variants were harvested with trypsin and washed into RPMI with no serum. Cells were equilibrated at 37°C for 15 minutes and then stimulated with a mixture of 750 μM H2O2 and 1 μM sodium orthovanadate (pervanadate) at 37°C for 5 minutes. Lysates and immunoprecipitates were prepared as described above. PY-20 Ab (Zymed) was used to detect tyrosine phosphorylation.
HEK293T cells were seeded in six-well plates and allowed to grow overnight. Bax-overexpression-induced apoptosis assays were then performed as described previously (Gao et al., 2003). A portion of the lysate was also subjected to SDS-PAGE and immunoblotted. Values for caspase activation were normalized by setting the value for vector cells treated with etoposide to 1.0. For pooled data, individual data points from multiple experiments performed in triplicate were combined to determine the mean±s.d. Quantified apoptosis data are shown as the mean±s.d. P values were derived using an unpaired Student's t test.
Examination of etoposide-induced cell death in REN cells was performed as described previously (Bergom et al., 2006). Quantified apoptosis data are shown as the mean±s.d. of representative results of at least three experiments performed in duplicate or triplicate. Values for control-siRNA-expressing cells treated with high-dose etoposide were normalized to 1.0. P values were derived using an unpaired Student's t test.
This work was supported by grants HL-40926 (to P.J.N.) from the National Heart, Lung, and Blood Institute of the National Institutes of Health, and by a P.E.O. Scholar Award (to C.B.) from the P.E.O. Foundation.